Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Catalyst Pharmaceuticals (CPRX) Tops Q3 EPS by 78c, Beats on Revenue; Offers FY23 Revenue Guidance
November 8, 2023 4:29 PM ESTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 EPS of $0.49, $0.78 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $102.7 million versus the consensus estimate of $100.37 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2023 revenue of $390-395 million, versus the consensus of... More
